A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Phase 1b Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
Epistemonikos ID: 8bdd4d12816c6fc1059cdbf24c085520675d72b1
First added on: Aug 28, 2025